WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998052577) GANGLIOSIDE GM3 INDUCED APOPTOSIS OF NEURAL CELLS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/052577    International Application No.:    PCT/US1998/010390
Publication Date: 26.11.1998 International Filing Date: 22.05.1998
Chapter 2 Demand Filed:    04.12.1998    
IPC:
A61K 31/70 (2006.01), A61K 31/7032 (2006.01), A61K 45/00 (2006.01), A61P 25/00 (2006.01), A61P 35/00 (2006.01), A61P 43/00 (2006.01)
Applicants: CASE WESTERN RESERVE UNIVERSITY [US/US]; 10900 Euclid Avenue, Cleveland, OH 44106 (US) (For All Designated States Except US).
MILLER, Robert, H. [GB/US]; (US) (For US Only).
NOLL, Elizabeth [US/US]; (US) (For US Only).
NAKASUJI, Yuji [JP/US]; (US) (For US Only).
BLACK, Peter, McLaren [CA/US]; (US) (For US Only)
Inventors: MILLER, Robert, H.; (US).
NOLL, Elizabeth; (US).
NAKASUJI, Yuji; (US).
BLACK, Peter, McLaren; (US)
Agent: MINNICH, Richard, J.; Fay, Sharpe, Beall, Fagan, Minnich & McKee, 7th floor, 1100 Superior Avenue, Cleveland, OH 44114-2518 (US)
Priority Data:
60/047,430 22.05.1997 US
Title (EN) GANGLIOSIDE GM3 INDUCED APOPTOSIS OF NEURAL CELLS
(FR) APOPTOSE DE CELLULES NEURONALES INDUITE PAR UN GANGLIOSIDE GM3
Abstract: front page image
(EN)The present invention relates to the ability of the ganglioside, GM3 to inhibit proliferation and induce apoptosis in proliferating CNS cells. The present invention further demonstrates the ability for GM3 to reduce cell numbers in primary cultures of rapidly proliferating human glial tumors and the 9L rat gliosarcoma cell line. In addition, GM3 is shown to have no effect on quiescent cultures of normal human CNS cells. A single injection of GM3 three days after intracranial implantation of tumor cells in a murine xenograft model system resulted in a significant increase in the symptom-free survival period of host animals. Therefore, GM3 is useful as a chemotherapeutic agent for human high grade gliomas.
(FR)La présente invention concerne l'aptitude du ganglioside, GM3, à inhiber la prolifération et à induire l'apoptose dans des cellules proliférantes CNS. L'invention concerne également l'aptitude de GM3 à réduire le nombre de cellules dans des cultures primaires de tumeurs gliales humaines proliférant rapidement et de la lignée cellulaire 9L du gliosarcome du rat. En outre, GM3 n'a aucun effet sur des cultures quiescentes de cellules CNS humaines. Une injection simple de GM3, trois jours après l'implantation intracrânienne de cellules tumorales dans un système murin constituant une hétérogreffe, provoque une augmentation significative de la période de survie sans symptôme chez des animaux hôtes. GM3 est, en outre, utilisé comme agent chimiothérapeutique destiné au traitement des gliomes très avancés chez l'homme.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)